Pharma News

Simple method develops white blood cells from human skin

  • Posted on: 12 September 2014
  • By: PharmaTutor News

(12th September, 2014); For the first time, scientists have turned human skin cells into transplantable white blood cells, soldiers of the immune system that fight infections and invaders. The work, done at the Salk Institute, could let researchers create therapies that introduce into the body new white blood cells capable of attacking diseased or cancerous cells or augmenting immune responses against other disorders.

4th International Congress on Patient Safety and 5th International Conference on Transforming Healthcare with IT 2014 hosted for the First Time in Eastern India by Apollo Gleneagles Hospitals

  • Posted on: 9 September 2014
  • By: PharmaTutor News

(9th September, 2014; Business Wire India); In its endeavour to build awareness and consciousness Apollo  Hospitals in association with ISQua, JCI, NABH and many other institutions hosted the 4th International Congress on Patient Safety along with the 5th edition of International Conference on Transforming Healthcare with IT 2014 for the first time in the Eastern part of the country. The two day event took place on 5th and 6th of September, 2014 at ITC Sonar, Kolkata.

Increased possibilities in India-Australia health care cooperation

  • Posted on: 7 September 2014
  • By: PharmaTutor News

(7th September, 2014); India and Australia are exploring cooperation possibilities in preventive healthcare, trauma care, geriatric medicine, diabetes research and mental illnesses. This found iteration in the dialogue held between the visiting Prime Minister of Australia, Mr Tony Abbott, and the Union Health Minister, Dr Harsh Vardhan, on 5th Sept, Friday.

Japan – India Cooperation in Healthcare: Rockland Takes the Initiative

  • Posted on: 5 September 2014
  • By: PharmaTutor News

(5th September, 2014; Business Wire India); “India & Japan have a big opportunity of working together in the area of healthcare. Japan has achieved its goal of longevity and healthy life for all its citizens. This knowledge and technology will benefit India as well as the rest of the world. Shri Narendra Modi, Hon’ble Prime Minister of India, has already extended an open invitation to COME MAKE IN INDIA.  India will give Japan a huge consuming population, excellent human resources and a low cost base for manufacturing and exporting healthcare solutions to the world”, said Rajesh Srivastava, Chairman, Rockland Hospitals. He was speaking on the topic: Creating Healthcare Access for Cancer Treatment: Sharing Japanese Solutions, during a two days seminar titled FICCI- Heal-2014 on 1 & 2 Sept in Delhi.

Florida scientists made Diseased Cells to synthesize their own drug to treat muscular dystrophy

  • Posted on: 4 September 2014
  • By: PharmaTutor News

(4th September, 2014); Florida Scientists from The Scripps Research Institute (TSRI) have considered chemical approach to convert diseased cells to be manufacturing site of a molecule which can treat muscular dystrophy. The promising research was published recently in the international chemistry journal Angewandte Chemie.

Mississippi Baby taught important HIV Lessons

  • Posted on: 3 September 2014
  • By: PharmaTutor News

(3rd September, 2014); The news in July that HIV had returned in a Mississippi toddler after a two-year treatment-free remission dashed the hopes of clinicians, HIV researchers and the public at large tantalized by the possibility of a cure. But a new commentary by two leading HIV experts at Johns Hopkins argues that despite its disappointing outcome, the Mississippi case and two other recent HIV "rebounds" in adults, have yielded critical lessons about the virus' most perplexing - and maddening - feature: its ability to form cure-defying viral hideouts.


Angiotensin receptor-neprilysin inhibitor opens new horizon in cardiac failure

  • Posted on: 3 September 2014
  • By: PharmaTutor News

(3rd September, 2014); The new agent, an angiotensin receptor-neprilysin inhibitor (ARNI) known as LCZ696, has already been granted Fast Track status by the United States Food and Drug Administration (FDA) – a designation which can expedite the review of new medicines intended to treat serious or life-threatening conditions. And surprisingly, LCZ696 was superior to ACE-inhibitor, enalapril, on key endpoints in the largest heart failure study ever done.

Two drugs from Wockhardt received Qualified Infectious Disease Product (QIDP) status from the USFDA

  • Posted on: 2 September 2014
  • By: PharmaTutor News

(2nd September, 2014); Wockhardt Ltd’s New Drug Discovery program in Anti - Infective research received a major boost after two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from the US FDA. This is the first instance of an Indian Pharmaceutical company receiving a QIDP status.

Extensive experience in clinical practice and expanding research programme support use of Pradaxa® for clot prevention

  • Posted on: 2 September 2014
  • By: PharmaTutor News

(2nd September, 2014; Business Wire India); Five years on from the first breakthrough presentation of the pivotal RE-LY® clinical trial of Pradaxa® (dabigatran etexilate) for the prevention of stroke in non-valvular atrial fibrillation (NVAF), extensive clinical trial and real-world data support Pradaxa® in various indications.Boehringer Ingelheim continues to grow the evidence base for Pradaxa® to improve care for patients at risk of blood clots and today announces the initiation of Phase III of the GLORIA™-AF registry program in North America and in Europe. During this final phase of the registry program, data on the overall safety and effectiveness of antithrombotic treatments will be collected.

Pages